Member Info for Bladderman

Also NCYT want to ramp up production to 8M a month. GDR at 10k per hour could produce (240k a day) or 8M a month also at maximum output. With testing of up to 100M a day potentially required going forward there's plenty of room for both in the market!

It's a one step very easy to use, highly sensitive robust test which ultimately will reduce human pipetting error. Yes the plates can be shipped ambiently which is a big plus for global distribution and storage

Most hospitals have diagnostic labs on site. The test result would be ready within an hour once samples are loaded

Amazing future here Scart

Yes it is misleading - what GDR have requires a piece of standard lab equipment which is present in all standard diagnostic labs (PCR) and is compatible with most brands. The beauty is a result is available within 40 minutes which is key to the COVID isolation strategy.

Only 4 trading days too next week (Mon-Thurs).

Here you go Marve
https://youtu.be/KpUfiPI6D9Y

https://www.pressreader.com/uk/the-guardian/20200502/282059099160731

RTPCR is one of the most sensitive techniques out there. By the way this is not an antigen or antibody test. It detects COVID specific RNA fragments and allows for greater mutation detection flexibility compared to other techniques.

It's no coindence Cytiva made a move here. We have passed the the critical technical validation milestones. Soon this will be 200p+ which is only £75M and will make a 'significant contribution' to global COVID testing. The WHO very much back the PCR approach and demand from the global market will send this relatively tiny MCap stratospheric

Nice - look forward to the weekend coverage! Massive weekend next week. Let's see if we can't knock at the door of 200p and see what happens. When the ii's start loading in we'll smash it easily

Be silly not to be holding some GDR

Couldn't ask for more guys.

Massive week here next week no doubt about that!

The force is strong with this one BigBench. Our one step easy test is being manufactured for the global market/stage. The tech validation RNS this morning is the confidence and confirmation that we needed to go to the next level. GDR can significantly contribute to the COVID 19 global
testing roll out. Still under £50M but not for long one would envisage

I think with the increasing acknowledgement that we need to test test test this hot stock is only going to become increasing attractive - especially when we're way under £50M. The world needs a simple one step diagnostic test. It's been validated and now scale up in progress. Upon EU approval the doors will likely be blown off. Preorders or distribution disclosure is going to really sober up the market to this gem.
At £50M ii's can start buying so I'm excited about that. NCYT peaked at £350M so at 10k per day test production I'd like to see £100M + this month. New money still pouring in today

So much for a lunch time slow down. Volume picking up nicely

And a £20k sell (for balance)

Mates rates....

That would make very good sense Technik. Danaher Corp, Cytiva's $20billion ownership company, would say there is no need to go to market.

'Non-dilutive funding' is an option disclosed by GDR but this company will have product to market in 3 weeks time and at 10k test production per hour this will be cash rich in no time

Just sent admin an email